Abstract 79 Table 1

EndpointsNaïve (n=199)Memory (n=156)Detectable anti-HLA (n=147)P-value
2 Year Survival 86.4% 87.3% 89.6% 0.660
2 Year Freedom from DSA Development 92.4% 84.3%* 77.7%** 0.001
1 Year Freedom from Any-Treated Rejection 82.5% 86.1% 80.5% 0.350
1 Year Freedom from Acute Cellular Rejection 90.4% 92.9% 95.5% 0.183
1 Year Freedom from Antibody-Mediated Rejection 98.0% 96.3% 89.9% 0.003
1 Year Freedom from Biopsy-Negative Rejection 92.2% 94.1% 92.9% 0.748
  • *p=0.051 in comparison to Naïve patients **p<0.001 in comparison to Nave patients